High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

Richard F. Schlenk, U. Germing, F. Hartmann, A. Glasmacher, I. T. Fischer, F. del Valle y Fuentes, K. Götze, H. Pralle, C. Nerl, H. Salwender, W. Grimminger, A. Petzer, M. Hensel, A. Benner, L. Zick, K. Döhner, S. Fröhling, H. Döhner

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m2 q12h, days 1-3; mitoxantrone 10 mg/m2, days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapse-free survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 × 109/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach.

Original languageEnglish
Pages (from-to)978-983
Number of pages6
JournalLeukemia
Volume19
Issue number6
DOIs
StatePublished - Jun 2005

Keywords

  • Activating FLT3 mutations
  • Acute promyelocytic leukemia
  • Additional chromosomal aberrations
  • High-dose cytarabine

Fingerprint

Dive into the research topics of 'High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this